ArticleRespiratory research2022
Plasma markers of COVID-19 severity: a pilot study.
Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Prevalence of hypertension in severe vs. non-severe COVID-19: a systematic review and meta-analysis.Journal of human hypertension · 2026Pooled it
- Total plasma N-glycomic patterns of COVID-19 disease.Glycoconjugate journal · 2026Article
- Glycosylation Variability of Serum α1-Acid Glycoprotein in the Context of Developing Inflammation and Oxidative Stress in Patients with Severe COVID-19.International journal of molecular sciences · 2025Article
- Risk factors for severe COVID-19 and development of a predictive model.BMC pulmonary medicine · 2025Article
- Glycosphingolipids as emerging attack points in bladder cancer.Discover oncology · 2025Review
- The Glycosylation of Serum IgG Antibodies in Post-COVID-19 and Post-Vaccination Patients.International journal of molecular sciences · 2025Article
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
- Characterization of alpha-1 antitrypsin in a Pi∗ZZ patient with emphysema: a case report.Respiratory medicine case reports · 2025Article
- Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production.Animal cells and systems · 2025Article
- Development and validation of nomogram models for severe and fatal COVID-19.Scientific reports · 2024Article
- Acute phase proteins patterns as biomarkers in bacterial infection: Recent insights.Open veterinary journal · 2024Review
- Clinical glycoproteomics: methods and diseases.MedComm · 2024Review
- The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024Review
- Total plasmaiScience · 2024Article
- Anion Exchange Chromatography-Mass Spectrometry to Characterize Proteoforms of Alpha-1-Acid Glycoprotein during and after Pregnancy.Journal of proteome research · 2024Article
- Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.Clinical and experimental medicine · 2024Article
- α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage.Biomarkers in medicine · 2024Article
- Accumulation of oxysterols in the erythrocytes of COVID-19 patients as a biomarker for case severity.Respiratory research · 2023Article
- The Alterations of Serum N-glycome in Response to SARS-CoV-2 Vaccination.International journal of molecular sciences · 2023Article
- Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSARS-CoV-2 infected patients show heterogeneous clinical presentations ranging from mild symptoms to severe respiratory failure and death. Consequently, various markers reflect this wide spectrum of disease presentations.
methodsOur pilot cohort included moderate (n = 10) and severe (n = 10) COVID-19 patients, and 10 healthy controls. We determined plasma levels of nine acute phase proteins (APPs) by nephelometry, and full-length (M65), caspase-cleaved (M30) cytokeratin 18, and ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motif 13) by ELISA. In addition, we examined whole plasma N-glycosylation by capillary gel electrophoresis coupled to laser-induced fluorescence detection (CGE-LIF).
resultsWhen compared to controls, COVID-19 patients had significantly lower concentrations of ADAMTS13 and albumin (ALB) but higher M30, M65, α1-acid glycoprotein (AGP), α1-antitrypsin (AAT), ceruloplasmin (CP), haptoglobin (HP), and high-sensitivity C-reactive protein (hs-CRP). The concentrations of α1-antichymotrypsin (ACT), α2-macroglobulin (A2MG) and serum amyloid A (SAA) proteins did not differ. We found significantly higher levels of AAT and M65 but lower ALB in severe compared to moderate COVID-19 patients. N-glycan analysis of the serum proteome revealed increased levels of oligomannose- and sialylated di-antennary glycans and decreased non-sialylated di-antennary glycan A2G2 in COVID-19 patients compared to controls.
conclusionsCOVID-19-associated changes in levels and N-glycosylation of specific plasma proteins highlight complexity of inflammatory process and grant further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.